27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
There were statistically significant improvements in resident well-being (Δ = 0.44, p = 0.029), Positive Engagement Potential (Δ = 0.17, p = 0.002), and Occupational Diversity (Δ = 0.12, p = 0.014) in 2016. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
We conducted a participatory research project to address this important area of care. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Assisted living provides housing and long-term care services to more than 811,000 older adults in the United States daily and is regulated by the states. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Participants comprised of registered nurses (N = 4), care assistants (N = 8), bereaved relatives (N = 7), and domiciliary staff (N = 3). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
We found the fundamental purpose of occupation is to support the person living with dementia to feel they are living a meaningful and fulfilling life. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Prior research suggests that a scarcity of dementia specialists could hamper access to disease-modifying Alzheimer's treatments. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
We had 38,777 and 40,277 hits for depression and dementia, respectively, in long-term care facilities or nursing homes. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The purpose of this study was to use routinely collected resident assessment data from a single site to evaluate the impact of COVID-19 restrictions on cognition, physical function and behavioral symptoms of residents with dementia. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
It is estimated that 5.4 million Americans have some form of dementia and these numbers are expected to rise in the coming decades, leading to an unprecedented demand for memory care housing and services. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Care of the dementia patient continues to be challenging. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Palliative care including hospice care is appropriate for advanced dementia, but policy initiatives and implementation have lagged, while treatment may vary. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
At time of death, the majority of decedents with dementia had advance directives, health care agents, and previous goals of care conversations with their caregiver. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
We found dilemmas regarding palliative care to be the main theme, including definition of the disease as terminal, choosing "comfort" over "life-prolonging," clarifying patients' wishes and deciding whether or not to use artificial feeding. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
High management support aligned with implementation effectiveness within NHs. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Patients in Group 1 were on statistically significant fewer medications than Group 2 at both week 4 and weeks 7-12 following admission. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Lewy body dementia (LBD) is asynucleinopathy that results in clinical manifestation of motor and neuropsychiatric symptoms. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
White respondents lived a greater percentage of their remaining lives cognitively healthy than their minority Black or Hispanic counterparts, regardless of level of education. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Extensive literature in the United States documents racial/ethnic and gender disparities in the incidence and prevalence of dementia yet few studies have examined how race/ethnicity and gender intersect to shape inequalities in the risk of dementia. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
DISCLOSURES: Funding for this summary was contributed by Arnold Ventures, The Donaghue Foundation, Harvard Pilgrim Health Care, and Kaiser Foundation Health Plan to the Institute for Clinical and Economic Review (ICER), an independent organization that evaluates the evidence on the value of health care interventions. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The total healthcare cost of ADD was JPY 1,073 billion, of which 86% (JPY 923 billion) was attributed to healthcare costs other than ADD drug costs (JPY 151 billion). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The annual cost of care per patient with mild to moderate and severe major MCD was INR 78288 and INR 167808, respectively. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Recognizing that the "healthcare sector perspective" can be too limited in some situations, the National Institute of Health and Care Excellence (NICE), Institute for Clinical and Economic Review (ICER), and the U.S. Second Panel on Cost-Effectiveness in Health and Medicine all recommend a "societal" perspective in "reference case" cost-effectiveness analyses (CEAs). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Wearable devices have found numerous applications in healthcare ranging from physiological diseases, such as cardiovascular diseases, hypertension and muscle disorders to neurocognitive disorders, such as Parkinson’s disease, Alzheimer’s disease and other psychological diseases. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
MTL 11C-acetate SUVR was significantly elevated in MCI compared to cognitively normal participants (P = 0.03; Cohen d = 1.76). 4 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Activation of glial cells and neuroinflammation play an important role in the onset and development of Alzheimer's disease (AD). 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →